亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma.

医学 吉西他滨 化疗 诱导化疗 顺铂 阶段(地层学) 内科学 外科 肿瘤科 紫杉醇 胃肠病学 生物 古生物学
作者
Sung Hoon Choi,Beodeul Kang,Jaekyung Cheon,Hongjae Chon,Dae Jung Kim,Chang‐Il Kwon,Kwang Hyun Ko
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:40 (4_suppl): 387-387
标识
DOI:10.1200/jco.2022.40.4_suppl.387
摘要

387 Background: In a recent phase II trial, nab-paclitaxel plus gemcitabine-cisplatin (Gem/Cis/nab-P) demonstrated prolonged survival and unprecedentedly high response rate in patients with advanced cholangiocarcinoma following treatment. We aimed to evaluate the clinical feasibility of this triplet chemotherapy as induction chemotherapy in patients with locally advanced cholangiocarcinoma. Methods: We retrospectively reviewed patients with locally advanced cholangiocarcinoma who were treated with Gem/Cis/nab-P between October 2019 to December 2020. Resectability after induction chemotherapy was evaluated by a multidisciplinary team. Treatment response and surgical pathology were reviewed. Results: Of the 85 patients were included in this study. 46 (54.1%) had measurable lesions. The objective response rate (ORR) and disease control rate in patients with measurable disease were 51.1% and 85.1%, respectively. Fifty-two (61.2%) patients were determined as resectable. Four patients that were judged to be resectable did not undergo surgery due to patient refusal or poor performance status after chemotherapy. Finally, 48 out of 85 patients (56.5%) underwent subsequent curative surgery after induction chemotherapy. There were six complete remission cases (12.5%) in the final pathology, which all reported patients with extrahepatic cholangiocarcinoma. R0 resection was achieved in 46 out of the 48 patients (95.8%). Despite the initial locally advanced cholangiocarcinoma, a pathologic T stage of less than T2 was reported in 44 (95.7%) patients. Lymph node metastasis was confirmed in 13 (27.1%) patients. The overall survival rates in patients who had chemotherapy followed by surgery was better than in those treated with chemotherapy alone ( P = 0.009). Conclusions: Gem/Cis/nab-P as induction chemotherapy showed promising efficacy and clinical feasibility before curative surgery in patients with locally advanced cholangiocarcinoma. This study showed that triplet chemotherapy using Gem/Cis/nab-P has a clear down-staging effect through a high response rate in patients with cholangiocarcinoma
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Sakura完成签到 ,获得积分10
7秒前
lihongchi完成签到,获得积分10
13秒前
宣灵薇完成签到 ,获得积分0
29秒前
火火完成签到 ,获得积分10
1分钟前
2分钟前
2分钟前
奋斗的杰发布了新的文献求助10
2分钟前
krajicek完成签到,获得积分10
2分钟前
3分钟前
TYJ10002发布了新的文献求助10
3分钟前
3分钟前
chiyudoubao发布了新的文献求助10
3分钟前
阳阳阳完成签到 ,获得积分10
4分钟前
4分钟前
搞钱发布了新的文献求助10
4分钟前
4分钟前
搞钱完成签到,获得积分10
4分钟前
lisasaguan完成签到,获得积分10
4分钟前
RED发布了新的文献求助10
5分钟前
5分钟前
634301059发布了新的文献求助20
5分钟前
5分钟前
yaoyao发布了新的文献求助10
5分钟前
乐乐应助yaoyao采纳,获得10
5分钟前
ktw完成签到,获得积分10
5分钟前
hahahan完成签到 ,获得积分10
6分钟前
跳跃的谷雪完成签到 ,获得积分10
6分钟前
9527z完成签到,获得积分10
7分钟前
LouieHuang完成签到,获得积分10
8分钟前
招水若离完成签到,获得积分10
8分钟前
可爱的函函应助奋斗的杰采纳,获得10
8分钟前
lkk183完成签到 ,获得积分10
9分钟前
10分钟前
yaoyao发布了新的文献求助10
10分钟前
10分钟前
奋斗的杰发布了新的文献求助10
10分钟前
科研通AI2S应助奋斗的杰采纳,获得10
11分钟前
CC完成签到 ,获得积分10
11分钟前
11分钟前
Nancy0818完成签到 ,获得积分10
12分钟前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3162323
求助须知:如何正确求助?哪些是违规求助? 2813330
关于积分的说明 7899707
捐赠科研通 2472848
什么是DOI,文献DOI怎么找? 1316528
科研通“疑难数据库(出版商)”最低求助积分说明 631365
版权声明 602142